Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Rituximab Combined with Steroid and Tacrolimus Treats Proliferative Glomerulonephritis with Monoclonal IgG Deposits: A Case Report and Review of the Literature

In Press, (this is not the final "Version of Record"). Available online 20 February, 2024
Author(s): Di Liu, Ming Xia, Chang Wang, Xuejing Zhu, Guochun Chen and Hong Liu*
Published on: 20 February, 2024

DOI: 10.2174/0109298673272183240108093135

Price: $95

Abstract

Introduction: Due to the confounding heterogeneity, the therapeutic strategy for proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) remains to be defined.

Case Representation: We report a 38-year-old man with recurrent swelling of the eyelids and lower limbs, undergoing rituximab combined with steroid and tacrolimus treatment, who achieved an improved renal outcome. Underlying solid malignant tumours were excluded from the diagnosis.

Discussion: We treated patients with rituximab along with steroids and tacrolimus. Improvements in proteinuria and renal function were observed. We also reviewed the current literature to assess the efficacy of rituximab in the treatment of PGNMID.

Conclusion: However, a larger pool of patients and a longer follow-up period are required to establish the role of rituximab and steroids in the treatment of PGNMID.

[1]
Nasr, S.H.; Markowitz, G.S.; Stokes, M.B.; Seshan, S.V.; Valderrama, E.; Appel, G.B.; Aucouturier, P.; D’Agati, V.D. Proliferative glomerulonephritis with monoclonal IgG deposits: A distinct entity mimicking immune-complex glomerulonephritis. Kidney Int., 2004, 65(1), 85-96.
[http://dx.doi.org/10.1111/j.1523-1755.2004.00365.x] [PMID: 14675039]
[2]
Nasr, S.H.; Satoskar, A.; Markowitz, G.S.; Valeri, A.M.; Appel, G.B.; Stokes, M.B.; Nadasdy, T.; D’Agati, V.D. Proliferative glomerulonephritis with monoclonal IgG deposits. J. Am. Soc. Nephrol., 2009, 20(9), 2055-2064.
[http://dx.doi.org/10.1681/ASN.2009010110] [PMID: 19470674]
[3]
Nada, R.; Gowda, K.K.; Ramachandran, R.; Joshi, K.; Tewari, R.; Kohli, H.S.; Jha, V.; Gupta, K.L. Proliferative glomerulonephritis with monoclonal immunoglobulin deposition disease: The utility of routine staining with immunoglobulin light chains. Indian J. Nephrol., 2015, 25(6), 344-348.
[http://dx.doi.org/10.4103/0971-4065.151354] [PMID: 26664209]
[4]
Bridoux, F.; Javaugue, V.; Nasr, S.H.; Leung, N. Proliferative glomerulonephritis with monoclonal immunoglobulin deposits: A nephrologist perspective. Nephrol. Dial. Transplant., 2021, 36(2), 208-215.
[http://dx.doi.org/10.1093/ndt/gfz176] [PMID: 33494099]
[5]
Aucouturier, P.; D’Agati, V.D.; Ronco, P. A fresh perspective on monoclonal gammopathies of renal significance. Kidney Int. Rep., 2021, 6(8), 2059-2065.
[http://dx.doi.org/10.1016/j.ekir.2021.04.026] [PMID: 34386655]
[6]
Barbour, S.J.; Beaulieu, M.C.; Zalunardo, N.Y.; Magil, A.B. Proliferative glomerulonephritis with monoclonal IgG deposits secondary to chronic lymphocytic leukemia. Report of two cases. Nephrol. Dial. Transplant., 2011, 26(8), 2712-2714.
[http://dx.doi.org/10.1093/ndt/gfr251] [PMID: 21633102]
[7]
Nasr, S.H.; Sethi, S.; Cornell, L.D.; Fidler, M.E.; Boelkins, M.; Fervenza, F.C.; Cosio, F.G.; D’Agati, V.D. Proliferative glomerulonephritis with monoclonal IgG deposits recurs in the allograft. Clin. J. Am. Soc. Nephrol., 2011, 6(1), 122-132.
[http://dx.doi.org/10.2215/CJN.05750710] [PMID: 20876681]
[8]
Tsuji, T; Miura, M; Yanai, M De novo proliferative glomerulonephritis with monoclonal IgG deposits of the IgG1kappa subtype in a kidney allograft. Nephrology, 2016, 21(S1), 44-47.
[9]
Merhi, B.; Patel, N.; Bayliss, G.; Henriksen, K.J.; Gohh, R. Proliferative glomerulonephritis with monoclonal IgG deposits in two kidney allografts successfully treated with rituximab. Clin. Kidney J., 2017, 10(3), 405-410.
[http://dx.doi.org/10.1093/ckj/sfx001] [PMID: 28616219]
[10]
Torrealba, J.; Gattineni, J.; Hendricks, A.R. Proliferative glomerulonephritis with monoclonal immunoglobulin G lambda deposits: Report of the first pediatric case. Case Rep. Nephrol. Dial., 2018, 8(1), 70-75.
[http://dx.doi.org/10.1159/000488641] [PMID: 29850460]
[11]
Xing, G.; Gillespie, R.; Bedri, B.; Quan, A.; Zhang, P.; Zhou, X.J. Proliferative glomerulonephritis with monoclonal IgG deposits in children and young adults. Pediatr. Nephrol., 2018, 33(9), 1531-1538.
[http://dx.doi.org/10.1007/s00467-018-3949-8] [PMID: 29616329]
[12]
Maan, D.; Clark, B.; Bunker, M.; Arora, S. Successful management of proliferative glomerulonephritis with monoclonal immune deposits with combined immunosuppressive therapy. BMJ Case Rep., 2018, 11(1), e225205.
[http://dx.doi.org/10.1136/bcr-2018-225205] [PMID: 30567197]
[13]
Wen, J.; Wang, W.; Xu, F.; Chen, J.; Zhang, M.; Cheng, D.; Ni, X.; Li, X.; Liu, Z. Clinicopathological analysis of proliferative glomerulonephritis with monoclonal IgG deposits in 5 renal allografts. BMC Nephrol., 2018, 19(1), 173.
[http://dx.doi.org/10.1186/s12882-018-0969-3] [PMID: 29996809]
[14]
Gumber, R.; Cohen, J.B.; Palmer, M.B.; Kobrin, S.M.; Vogl, D.T.; Wasserstein, A.G.; Nasta, S.D.; Bleicher, M.B.; Bloom, R.D.; Dember, L.; Cohen, A.; Weiss, B.M.; Hogan, J.J. A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits. Kidney Int., 2018, 94(1), 199-205.
[http://dx.doi.org/10.1016/j.kint.2018.02.020] [PMID: 29759418]
[15]
Sawada, A; Kawanishi, K; Horita, S Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits complicated by immunoglobulin A nephropathy in the renal allograft. Nephrology, 2016, 21(S1), 48-52.
[16]
Buxeda, A.; Said, S.M.; Nasr, S.H.; Leung, N.; El Ters, M.; Cosio, F.G. Recurrent proliferative glomerulonephritis with monoclonal immunoglobulin deposits in kidney allografts treated with anti-CD20 antibodies. Transplantation, 2019, 103(7), 1477-1485.
[http://dx.doi.org/10.1097/TP.0000000000002577] [PMID: 30747850]
[17]
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int., 2021, 100(4S), S1-S276.
[PMID: 34556256]
[18]
Li, Y.; Fu, R.; Gao, J.; Wang, L.; Duan, Z.; Tian, L.; Ge, H.; Ma, X.; Zhang, Y.; Li, K.; Xu, P.; Tian, X.; Chen, Z. Effect of pulsed intravenous methylprednisolone with alternative low-dose prednisone on high-risk IgA nephropathy: A 18-month prospective clinical trial. Sci. Rep., 2022, 12(1), 255.
[http://dx.doi.org/10.1038/s41598-021-03691-0] [PMID: 34996948]
[19]
Zhao, J.; Ma, F.; Bai, M.; Sun, S. Low-dose corticosteroid combined with mycophenolate mofetil for IgA Nephropathy with stage 3 or 4 CKD: A retrospective cohort study. Clin. Ther., 2021, 43(5), 859-870.
[http://dx.doi.org/10.1016/j.clinthera.2021.03.009] [PMID: 33863547]
[20]
Shengyou, Y.; Li, Y.; Zhihong, H.; Yuanyuan, M. Influence of tacrolimus on podocyte injury inducted by angiotensin II. J. Renin Angiotensin Aldosterone Syst., 2015, 16(2), 260-266.
[http://dx.doi.org/10.1177/1470320314568520] [PMID: 25650384]
[21]
Zhang, S.; Wang, H.; Liu, Y.; Yang, W.; Liu, J.; Han, Y.; Liu, Y.; Liu, F.; Sun, L.; Xiao, L. Tacrolimus ameliorates tubulointerstitial inflammation in diabetic nephropathy via inhibiting the NFATc1/TRPC6 pathway. J. Cell. Mol. Med., 2020, 24(17), 9810-9824.
[http://dx.doi.org/10.1111/jcmm.15562] [PMID: 32779844]
[22]
Ma, R; Wang, Y; Xu, Y. Tacrolimus protects podocytes from apoptosis via downregulation of TRPC6 in diabetic nephropathy. J. Diabetes. Res, 2021, 8832114.
[PMID: 34095318] [PMCID: PMC8163546]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy